Google DeepMind releases AlphaGenome 2 for cell-specific disease research
Cell-specific variant interpretation is a bottleneck in translating genome sequencing into clinical insight, and AlphaGenome 2 targets exactly that gap. Genomics labs, computational biologists, and biotech teams evaluating disease-causing mutations can use it to prioritise variants by affected tissue. Compared with AlphaFold, which resolved protein structure, this model moves DeepMind's tooling upstream into gene regulation, a space where competitors like Enformer and Evotec partnerships have been active.
